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Abstract
Cancer genetic testing (CGT) is a powerful diagnostic test that improves cancer prevention and early detection among
individuals at high genetic risk of cancer. Since the completion of the mapping of the Human Genome Project, CGT has
become increasingly available in the clinical setting. However, as gene discovery and sequencing technology improve, the
impact of these advancements on patients is less understood. The use of multigene cancer gene panel tests has become
increasingly prevalent; as such, the likelihood of incidental or inconclusive findings has increased. The author conducted a
literature review to outline the science on CGT methods, the psychosocial responses to testing among patients, and the
unique role of nurses in this process. A significant gap in the literature exists regarding multigene cancer genetic panel tests
and the associated experiences and decision-making processes among individuals who have had testing. Future research
will specifically explore the experiences of young women with breast cancer who have undergone hereditary cancer risk
assessment genetic panel testing that reveals incidental or inconclusive findings.
Keywords
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Introduction
In 2018, some 1,735,350 people in the United States will be
diagnosed with cancer (American Cancer Society, 2018).
The emotional stress of receiving a cancer diagnosis is a devastating setback. Physical and psychological impairments
associated with the discovery of cancer may lead to an inability to carry out normal, everyday activities for any person.
More specifically, female patients under the age of 45 who
are diagnosed with cancer may experience increased psychosocial distress attributed to the feeling of having much life
left to live and many responsibilities to maintain. Women
under 45 are most commonly diagnosed with breast, colorectal, and lung cancers (American Cancer Society, 2018). As
many as one in 19 women in the United States will be diagnosed with some form of cancer before the age of 45
(American Cancer Society, 2018).
Fortunately, in the past 20 years, cancer detection and
early prevention measures have improved significantly.
Providers now employ cancer genetic testing (CGT) for early
identification of hereditary cancer syndromes, allowing for
earlier identification and prevention of cancer (Baylin &
Jones, 2012; Matloff, Bonadies, Moyer, & Brierley, 2014).
More than 200 hereditary cancer syndromes have been identified in cancer research. These syndromes account for 5% to
10% of all cancer, with breast, colon, and/or endocrine neoplasia being the most highly penetrant. A susceptibility to

inherited cancer is suspected with characteristics such as a
diagnosis of the same type of cancer in two or more relatives
on the same side of the family, more than one generation
affected, and/or early age of diagnosis (Nagy, Sweet, & Eng,
2004).
Still, the presence of a cancer-predisposing mutation in a
family does not guarantee cancer development. Other factors
such as patterns of inheritance determine cancer development. Autosomal dominant inheritance causes a single
altered copy of a gene to increase a person’s likelihood of
cancer development. In this case, the person’s parent may
also present effects of the mutation. Autosomal recessive
inheritance gives a person an increased risk of cancer only if
they inherit a mutated copy of the gene from both parents.
Finally, X-linked recessive inheritance occurs when a female
with a recessive cancer-predisposing mutation on one of her
X chromosomes passes a copy of the gene to her son, who
will then only have a copy of the altered chromosome and a
resulting increased risk of cancer (National Cancer Institute,
2016). With increases in knowledge of hereditary cancer
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syndromes, CGT has become a standard of care in oncology
and, increasingly, primary care settings.

The Role of CGT
CGT is a powerful means to discover deleterious mutations
in a patient’s genes. In its simplest form, this technology
allows for patients to know whether they are at increased risk
of cancer beyond general population risk. It also allows individuals to make informed choices about cancer risk reduction, and if cancer is diagnosed, that it is done so at earlier
stages (National Cancer Institute, 2016).
The primary reason people choose to undergo CGT is
because of personal and/or positive family history of cancer
(Burt & Neklason, 2005; Facing Our Risk of Cancer
Empowered [FORCE], 2016; Gomy & Estevez Diz, 2013). A
family history of a blood relative with a known mutation in a
gene that increases cancer risk, a blood relative with two or
more primary breast cancers, two or more relatives with
breast cancer on the same side of the family with at least one
diagnosed before age 50, or a blood relative with ovarian
cancer are among various risk factors that increase a person’s
likelihood of having a mutation themselves (FORCE, 2016).
In addition, anyone with a personal or family history of three
or more cancers such as pancreatic, prostate, melanoma, sarcoma, adrenal, brain, leukemia, uterine, or other cancers also
maintain a higher risk of deleterious mutation themselves
(FORCE, 2016; Stoffel & Chittenden, 2010) Other reasons
for undergoing CGT include having a family member or
members who have had cancer at a younger age than normal
(50 years or younger) or a family history of a known genetic
mutation (Burt & Neklason, 2005; FORCE, 2016; Stoffel &
Chittenden, 2010). Ethnicity is another determining factor in
choosing to partake in genetic testing as well as any physical
evidence that may be linked to an inherited cancer. For
example, individuals who are Eastern European Jewish have
a higher risk of carrying specific mutations in BRCA1 and
BRCA2 genes (American Cancer Society, 2018).
The approach to genetic testing is analogous for all hereditary cancer syndromes (Burt & Neklason, 2005). A detailed
review of the patient’s family history is first obtained to identify any probable genetic mutations (Burt & Neklason, 2005;
National Cancer Institute, 2016).
Patients then attend genetic counseling, where informed
consent for testing for a genetic mutation is obtained
(American Academy of Pediatrics Committee on Bioethics,
2001; Gomy & Estevez Diz, 2013).

A Brief History of Genetic Testing
The study of genetics began in 1865 when Gregor Mendel
introduced the fundamental laws of inheritance (Mendel,
1865). Mendel’s contributions along with significant
advances in technology in the 20th century led to events such
as the proposition of a relationship between chromosomes
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and cancer by Theodor Boveri, a description of the double
helix structure of DNA by James Watson and Francis Crick,
and the innovation of the Sanger sequencing method by
Frederick Sanger (Boveri, 1929; Sanger, Nicklen, & Coulson,
1977; Watson & Crick, 1953). These discoveries allowed
scientists to develop genetic tests for conditions such as
Down syndrome, cystic fibrosis, and muscular dystrophy
(National Institutes of Health, 2010). By 1990, the Human
Genome Project was launched to reveal a complete map of
the human genome (Durmaz et al., 2015). The first report of
the Human Genome Project claimed that the human body
had 30,000 to 50,000 genes (Durmaz et al., 2015). The final
report of the Human Genome Project in 2003 revealed 93%
of the human genome and declared that the human genome
contained 20,000 to 25,000 protein-coding genes (Durmaz
et al., 2015). During the late 1990s, the study of genetics
focused on the central role of epigenetic processes regarding
disease causation (Baylin & Jones, 2012). Before long,
genetic testing became a standard procedure for clinical indications such as screening newborns for health conditions
(National Institutes of Health, 2010). In 1996, BRCA1 and
BRCA2 were cloned, shifting the focus of genetic testing to
cancer (Matloff et al., 2014).
In the past 10 years, CGT has evolved from a rare, costly
subspecialty to a practice that is a standard of care in the
cancer management continuum (Baylin & Jones, 2012;
Matloff et al., 2014). Recent gene sequencing techniques
have revolutionized the ability of scientists to recognize
nucleosome positioning and how changes in these contribute
to cancer (Kouzarides, 2007; Matloff et al., 2014). CGT is
used today to confirm hereditary cancer syndrome diagnoses
and serves as a path toward cancer prevention and early
treatment (Burt & Neklason, 2005).
Genetic panel testing is a widely used measure of modern
CGT. More specifically, genetic cancer panel testing is a process used to examine several different cancers and risk variants simultaneously (Hiraki, Rinella, Schnabel, Oratz, &
Ostrer, 2014; Meldrum, Doyle, & Tothill, 2011; Santos et al.,
2012). Because of their cost-effectiveness, panel tests permit
scientists to sequence multiple targets associated with cancer
risk (Hiraki et al., 2014). In addition, panel testing allows for
the testing of large amounts of gene targets to clearly understand a patient’s risks (Hiraki et al., 2014). Panel testing
yields various results that are explained to patients during
genetic counseling: positive, negative, true negative, uninformative negative, false negative, variant of unknown significance, and benign polymorphism (National Cancer
Institute, 2016).
Gene expression signatures are another up-and-coming
tool used to reveal clinically significant characteristics of
biological samples. These signatures are used to recognize
not only mutations in single genes but also distinct subtypes
of tumors. Gene signatures can identify cellular responses to
their environment and predict cancer outcomes, aiding in
cancer monitoring and treatment (Chang et al., 2011). A
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study conducted by the Champalimaud Clinical Center in
Lisbon, Portugal, examined MammaPrint, a 70-gene signature test, to determine its ability to predict clinical outcomes
for patients with early-stage breast cancer. This study examined 6,693 women with early-stage breast cancer and, using
the 70-gene signature test, determined their genomic risk.
Clinical risk was also identified using a modified version of
Adjuvant! Online. Women with a high clinical risk and low
gene signature risk who were not treated with chemotherapy
were found to have a 5-year rate of survival without metastasis, only 1.5 percentage points lower than those women who
did receive chemotherapy. The study concluded that some
46% of women with breast cancer and a high clinical risk
may not require chemotherapy (Cardoso et al., 2016). The
use of gene signatures alongside panel testing provides a
broadened view of a patient’s cancer recurrence risk to best
construct their treatment plan.
Despite great advances in CGT, no test has perfect predictability. The quality of cancer genetic tests is described by how
well the test determines who truly has the disease (sensitivity)
and by how well the test tells who does not have the disease
(specificity). A very sensitive test will detect even the slightest abnormal finding. Highly sensitive tests may leave cases
of cancer undetected, but may also result in false-positive
results. A test with high specificity will have fewer false-positive results, but will have more false negatives (Susan G.
Komen Foundation, 2018).
Currently, research is being carried out to identify stronger avenues of detecting and treating cancer among those
who are found to carry deleterious genetic mutations. In the
future, CGT and panel testing will continue to hold a crucial
role in cancer care. It is expected that the cost of genetic testing will continue to decline such that, eventually, a person’s
entire genome will cost less than US$1,000 to sequence
(National Institutes of Health, 2010).

The Nurse’s Role in Genetic Testing
At the forefront of holistic patient care, nurses’ responsibility
in CGT is becoming increasingly important. Nurses play a
crucial role in genetic-based practice and take on numerous
tasks such as gathering family history, assisting with
informed decision making, and providing genetic counseling
(Badzek, Calzone, Jenkins, Culp, & Bonham, 2013; Lea,
2008; Pasche & Absher, 2011). While there are specific credentials required to be an advanced practice nurse in genetics, Bachelor of Science in Nursing (BSN) programs across
the United States are in the process of revision to incorporate
essentials of the study of genetics into the curriculum
(Phillips, 2006). Overall, however, genetics is becoming less
of a specialty discipline and more of a standard factor in
everyday holistic nursing care (Umberger, Holston, Hutson,
& Pierce, 2013).
Very early in the CGT process, oncology nurses are
responsible for gathering patients’ cancer family history.
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During this time, nurses serve as an educator for patients,
teaching them about the importance of reviewing family history information when considering genetic testing (Lea,
2008). Nurses also construct pedigrees from family histories
to assess hereditary and nonhereditary disease risk factors
(Phillips, 2006). Finally, nurses are responsible for identifying potential genetic conditions or predisposition to disease
based on family history (Phillips, 2006).
Another important role of many oncology nurses is assisting with the informed patient decision-making process. After
a patient’s family history is assessed and discussed, it is crucial that patients be informed of the risks and benefits of
CGT, the possible outcomes of testing, and choice about
deciding to undergo testing (American Academy of Pediatrics
Committee on Bioethics, 2001; Lea, 2008). Nurses are
involved in all of these steps (Lea, 2008).
Advanced Practice Nurses in Genetics (APNGs) are specifically trained in the care of patients with genetic illnesses.
These advanced practice nurses assist patients and families
by assessing hereditary factors related to genetic conditions
such as cancer. They also serve as a liaison between patient
and physician for patient care management. APNGs acquire
their positions by first earning a BSN degree and then attaining a Master of Science in nursing in which they gain specialized clinical training in genetics (American Nurses
Credentialing Center [ANCC], 2016).
Genetic counseling is often facilitated by advanced practice nurses before and after CGT to translate genetic information to patients (Lea, 2008). Genetic counselors educate
patients on hereditary cancer syndromes as well as the overall CGT process and its outcomes. Patients are informed of
cancer prevention and management techniques, and available research on their cancer and are provided with resources
to aid them in their journey (National Cancer Institute, 2016).
Genetic counselors also educate patients on the physical and
psychological risks of learning their genetic test results,
along with the possibility of an uninformative result (National
Cancer Institute, 2016). Genetic counselors typically first
earn a bachelor’s degree in biology, social science, or nursing and later go on to participate in a master’s program
accredited by the American Board of Genetic Counseling
(National Society of Genetic Counselors [NSGC], 2016).
Historically, registered nurses have left much of genetic
practice to advanced practice nurses. Baccalaureate programs in nursing, however, are constantly undergoing revisions to incorporate further training in genetics into the
curriculum. Currently, required genomic-related competencies for registered nurses are separated into four categories:
nursing assessment, identification, referral activities, and
provision of education, care, and support (Phillips, 2006;
Umberger et al., 2013). BSN programs educate students to
consider genetic influences when considering appropriate
interventions and to evaluate the impact of treatments on
patient outcomes (Lea, 2008). Registered nurses are also
responsible for the facilitation of referrals for specialized
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genetic services for patients as needed. Unfortunately, challenges such as a lack of appreciation for the significance of
genetics in nursing practice, faculty unpreparedness, and a
lack of emphasis of genetics in RN licensure examinations
hinder the progress of genetics in nursing education
(Umberger et al., 2013). As CGT becomes more advanced,
nurses will be increasingly responsible for communicating
genetic information as an everyday part of cancer patient
care.

Psychosocial Implications of CGT
With constant improvements in technology and medicine for
oncology and genetics, participating in genetic testing will
become more and more commonplace for standard cancer
prevention and treatment. As the number of patients who
undergo CGT increases, so increases the necessity of understanding CGT. Specifically, it is important to further examine
the psychosocial impacts the results of genetic testing have
on patients (Patenaude & Julian-Reynier, 2008). Numerous
studies have been conducted to assess different aspects of
these psychosocial implications among different groups of
people.

Potential Psychosocial Concerns Associated With
CGT
Several authors have found that genetic testing leads to notable psychosocial implications. In fact, it has been suggested
that approximately one quarter of those who undergo CGT
acquire some level of distress, anxiety, or depression
(Pasacreta, 2003). One study conducted by the Swansea
University (n = 194) found that up to three quarters of those
who participated in their study reported concerns related to
their experience with testing (Bennett et al., 2012). Of these
concerns, over two thirds of participants reported apprehension and concern about how their families would react to
their results, implications for family members of an increased
risk result, and how participants would personally cope with
an increased risk result. Other responses included concerns
regarding the decision-making process based on testing
results and the overall impact of genetic risk of cancer on
lifestyle (Bennett et al., 2012).
Along these lines, another study conducted by the
Netherlands Cancer Institute (n = 127) sought to identify
specific psychosocial concerns related to genetic testing
and counseling and to create a questionnaire designed to
recognize these problems in individuals undergoing
genetic testing in the oncology setting (Eijzenga et al.,
2014). The survey developed in the study, the Psychosocial
Aspects of Hereditary Cancer (PAHC) questionnaire, contained 26 questions organized into six major categories of
identified problems: genetics, practical issues, family, living with cancer, emotions, and children (Eijzenga et al.,
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2014). The study concluded that when used in conjunction
with the Distress Thermometer—a visual analog scale
ranging from 0 to 10 to describe one’s distress—the PAHC
questionnaire was an effective first-line screener for psychosocial problems in candidates for genetic testing. Using
these measures, the study found need for increased psychosocial counseling after testing (Eijzenga et al., 2014;
Tuinman, Gazendam-Donofrio, & Hoekstra-Weebers,
2008).
While the studies above demonstrate noteworthy results
regarding concerns associated with CGT, several of them
possess important weaknesses as well. A few studies had
small or unrepresentative samples (Pasacreta, 2003). Other
studies were not performed in the United States (Bennett
et al., 2012; Eijzenga et al., 2014; Tuinman et al., 2008).
Furthermore, a few of the studies were carried out qualitatively, which may provide less insight into statistical evidence (Bennett et al., 2012; Eijzenga et al., 2014).

Predictors of Potential Psychosocial Concerns
Associated With CGT
Various factors have been attributed to a greater likelihood of
acquiring psychosocial problems for patients who participate
in CGT. According to one study in the Netherlands (n = 165),
researchers searched for prognostic factors to predict which
counselees were most likely to develop psychological problems after genetic testing (Voorwinden & Jaspers, 2016).
Male and female participants above the age of 18 with a 50%
or greater risk of BRCA1/2 or Lynch syndrome were surveyed
at three different points to determine factors contributing to
their emotional distress after testing (Voorwinden & Jaspers,
2016). Overall, authors concluded that worries regarding cancer after genetic testing were best predicted by preexisting
cancer worries, a positive deleterious result, a high-risk perception of getting cancer, and being single (Voorwinden &
Jaspers, 2016).
Hirschberg, Chan-Smutko, and Pirl (2015) also cited
numerous existential risk factors that contribute to stress and
anxiety regarding CGT. For example, a history of depression, use of medication, and high levels of distress at the time
of testing resulted in greater levels of distress after genetic
testing (Hirschberg et al., 2015). Whether or not a person had
lost a family member to a hereditary cancer, especially if an
individual lost a parent before the age of 13, was another
strong indicator of potential distress. Coping styles and
familial relationships also affected how a person handled the
stress of results from genetic testing. Those with positive
family relationships were more likely to adhere to counseling recommendations and displayed fewer symptoms of distress (Hirschberg et al., 2015). Finally, perceived risk and
distress at baseline played a large role in predicting stress,
especially in patients who overestimated their level of risk
(Hirschberg et al., 2015).
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A study conducted in Hong Kong, China (n =76) sought
to investigate the factors that predict psychological resilience
in adults undergoing genetic testing for hereditary colorectal
cancer. Researchers used a longitudinal design to test participants on four different occasions throughout 1 year (Ho, Ho,
Bonanno, Chu, & Chan, 2010). This study concluded that
baseline hope was a significant predictor of resilience for
those participating in genetic testing and suggested further
interventions to increase hope levels in patients to ease
potential psychosocial harm caused by genetic testing (Ho
et al., 2010).
Of the studies mentioned above, the most significant limitation is that much of the literature surrounding risk factors
for psychosocial distress associated with CGT is from other
countries (Bennett et al., 2012; Ho et al., 2010). Further
research in the United States may be necessary to determine
the significance of these findings related to the American
culture.

Potential Psychosocial Benefits Associated With
CGT
Many investigators have found that while psychosocial
implications may accompany CGT, symptoms such as
depression and anxiety are no higher in patients who undergo
testing than those who do not. A study conducted in 2011 was
designed to determine impacts of genetic testing on the psychological distress and cancer worry caused by genetic testing, as well as perceived advantages of testing claimed by
pancreatic cancer and melanoma patients (n = 60; Aspinwall,
Taber, Leaf, Kohlmann, & Leachman, 2013). Results showed
that participants who underwent genetic testing demonstrated decreases in anxiety, depression, and cancer worry
long term due to the knowledge of their test results (Aspinwall
et al., 2011). One participant noted feeling “more at ease for
[his or her] children’s sake” and that genetic testing granted
“choices and options for the better about taking steps to prevent” cancer (Aspinwall et al., 2011, p. 284). Other perceived
benefits of genetic testing claimed by participants included
the informational benefit of increased knowledge about melanoma risk and its management, as well as the benefit of
improved health behaviors and likelihood to increase practice of genetic screening (Aspinwall et al., 2011).
Another study that focused on patients undergoing genetic
testing for Lynch syndrome revealed that positive genetic
test results often lead to transient psychosocial repercussions. However, patients appeared to have no long-term
genetic testing–related depression or anxiety (Galiatsatos,
Rothenmund, Aubin, & Foulkes, 2015). In fact, most signs of
depression and anxiety related to genetic testing were seemingly normal by 6 to 12 months (Galiatsatos et al., 2015).
According to the previously mentioned study by Ho et al.
(2010), hereditary colorectal cancer patients who participated in this study exhibited little to no signs of depression or
anxiety the year after disclosure of their genetic test results

(Ho et al., 2010). It was concluded that a majority of those
tested for hereditary colorectal cancer were psychologically
resilient and exhibited little to no signs of depression immediately after genetic testing (Ho et al., 2010). In fact, only
8.7% of participants exhibited elevated symptoms of anxiety
and another 7.2% symptoms of depression caused by genetic
testing. Furthermore, it was estimated based on the results of
the study that the percentage of participants exhibiting testrelated anxiety and depression would decrease to 7% to 9%
by 12 months (Ho et al., 2010).
Voorwinden and Jaspers (2016) found that immediately
after genetic testing, counselees with an unfavorable result
demonstrated no more emotional distress than those with a
favorable result. It was not until 4 to 6 weeks after testing
those counselees with an unfavorable result demonstrated
increased levels of stress and concern regarding their genetic
testing results (Voorwinden & Jaspers, 2016).
Finally, a study measuring qualitative and quantitative
outcomes of females with breast cancer found genetic testing
to be psychologically advantageous to patients (SchlichBakker, ten Kroode, & Ausems, 2006). The investigators
concluded that females who participated in genetic testing
and genetic counseling experienced reductions in anxiety,
especially when counseling was tailored to their specific
needs (Schlich-Bakker et al., 2006).
Limitations surrounding the studies regarding psychosocial benefits associated with CGT include small sample size
(Aspinwall et al., 2011) and the lack of exploration regarding
various dynamics between nonmutation carriers such as
affected family member reactions, coping mechanisms of
partners of patients affected by a mutation, the impact of a
diagnosis on career, and professional goals. In addition, further research is necessary on the psychosocial aspects of
patients who decline CGT (Galiatsatos et al., 2015).

Ethical Implications of CGT
With constant advances in technology, CGT continues to
become less expensive and more affordable for many patients
at risk of cancer. Panel testing, in particular, is a widely used
tool for assessing genetic risk of multiple types of cancer.
Panel testing is a popular form of personalized medicine that
gives patients an objective response to understand their level
of risk for cancer (Hiraki et al., 2014). Despite its benefits,
however, panel testing presents various ethical dilemmas
that must be taken into consideration (Hanoch, Miron-Shatz,
Rolinson, & Ozanne, 2014; Hermel, McKinnon, Wood, &
Greenblatt, 2016; Hiraki et al., 2014; Ormond et al., 2010;
Surbone, 2001; Tabor et al., 2012; Tavtigian, Greenblatt,
Goldgar, & Boffetta, 2008).
Defining the target population for panel testing is one
challenge of using this approach. First, few people who wish
to undergo genetic testing even meet the criteria to warrant
testing of their specific cancer risk (Hiraki et al., 2014). For
example, the first step in CGT is assessing the family history
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(Gomy & Estevez Diz, 2013). Without a family history of
hereditary cancer, many people are ineligible for panel testing altogether, although they may still have concealed riskincreasing mutations that would be uncovered from genetic
testing (Hiraki et al., 2014). Furthermore, it is difficult to
determine who has the right to the information of an individual’s panel testing results. Antonella Surbone of Sloan
Kettering Cancer Center in New York (2001) asks, “Does the
daughter of a cancer patient have the right to know her mother’s BRCA status?” (p. 153). There is great ethical dilemma
between the determination of who has the right to know the
results of an individual’s genetic testing and the importance
of maintaining an individual’s confidentiality (Surbone,
2001).
Another challenge in panel testing lies within the issue of
informed consent. Informed consent requires that a patient
be presented with adequate information so that they are fully
aware of potential risks and benefits of a treatment before
agreeing to proceed (Ormond et al., 2010). Unfortunately,
providing a patient with all the details of potential strengths
and limitations of panel testing may lead to information
overload, inhibiting a patient’s proper decision-making ability (Hiraki et al., 2014). One study aimed to qualitatively
gain understanding about patient expectations and perceptions regarding the potential risks and benefits of genetic
testing (Tabor et al., 2012). This study found that traditional
approaches to informed consent were not appropriate for
genome sequencing and that these approaches often lead to
excessive burden on participants. Increased knowledge of
genetic risk can be life-altering, and obtaining ethical
informed consent for panel testing is an area of controversy
(Ormond et al., 2010).
Along these lines, genetic testing for children and adolescents presents another ethical dilemma. A study by Botkin
et al. (2015) reviewed the ethical, legal, and social implications of genetic testing in children. There are various heritable conditions for which genetic testing provides highly
predictive information about a patient’s future health status.
When it comes to children, this information leads to concerns regarding stigma and discrimination against children in
some circumstances (Botkin et al., 2015). Furthermore, children lack decision-making skills and are unable to give
informed consent for themselves. Parents usually provide
surrogate consent for their children with the child’s “best
interest” at heart, a highly contentious concept in itself.
While parents are generally the best-fitted surrogate consentgivers for their children, defining a child’s “best interest” is
multifaceted, and there are often cases when parents make
decisions that seem opposite of the best interest of their child
(Botkin et al., 2015). The ethical implications surrounding
the genetic testing of children necessitate further
investigation.
Perhaps the most significant challenge regarding cancer
panel testing is the difficulty surrounding interpretation and
communication of risk results between medical personnel
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and patients. Panel testing yields various results: a positive
result means that a known pathogenic mutation is detected,
a negative result means that no genetic variant is detected,
and an ambiguous result means that a variant of uncertain
significance (VUS) or benign polymorphism is detected
(Hiraki et al., 2014; Tavtigian et al., 2008). While both positive and negative results generally lead to relatively concise clinical decision making, an ambiguous result makes
things much more complicated. According to Tavtigian
et al. (2008), panel testing often finds “missense substitutions, potential splicing variants, or small in-frame insertion-deletions that are of uncertain significance” (p. 1261).
In addition, testing for multiple gene mutations at a time
increases the likelihood of producing a false-positive result
or of detecting a VUS. The problem with an ambiguous
VUS result is that there is little information regarding the
effect of these less common genetic variants (Hiraki et al.,
2014; Walsh et al., 2010). As a result, the data to provide
accurate genetic assessments are limited, making it difficult
to interpret risk and challenging to present risks to patients
(Hiraki et al., 2014). A study conducted by a Familial
Cancer Program in Vermont (n = 277) reviewed factors that
were potential predictors of variants of uncertain significance and assessed changes in management tactics based
on these factors (Hermel et al., 2016). Out of 227 patients,
67 patients had genetic variants and eight patients had multiple variants. Forty-four patients in the study had a VUS.
The study found that there were no single factors such as
age or personal neoplasm history that could predict variants
during panel testing. Only two cases where a VUS was
identified resulted in the alteration of the patients’ management tactics. Overall, it was noted that little could be done
about ambiguous results with today’s technology (Hermel
et al., 2016). The knowledge of the potential likelihood of
uncovering a genetic mutation without a means to understand or prevent the mutation is an ethical quandary that
must be taken into consideration. Furthermore, when conducting a panel test that searches for multiple mutations, it
is possible to discover that a patient may carry multiple
mutations or variants in multiple genes (Hiraki et al., 2014).
Exposing new cancer risks in addition to the risks the panel
test was looking for to begin with may be an unforeseen
disadvantage of panel testing that must be thoroughly discussed with patients. Discovering the risk of having passed
genetic mutations onto one’s child is an example of an
unanticipated implication of panel testing that is considered
ethically unsound (Rahman & Scott, 2007).
In addition to clinical uncertainty of results, patients
often struggle to understand the meaning of testing results.
A study conducted by the University of Plymouth in the
United Kingdom recruited 477 women at risk of breast and
ovarian cancer and asked them to interpret positive, truenegative, ambiguous, and uninformative-negative results
(Hanoch et al., 2014). While women were able to correctly
interpret positive and negative results, they struggled to
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understand the meaning of both uninformative and ambiguous results. When presented with uninformative-negative
results, approximately half of the women learned nothing
from the results. A substantial amount of women believed
an uninformative-negative result signified a mere average
probability of developing cancer. Other women believed
an uninformed-negative result signified a decrease in cancer development risk. Ambiguous results yielded similar
uncertainty in women’s interpretations. Over half of the
sample viewed the ambiguous results as uninformative,
40% saw ambiguity as an average risk of cancer, and a
minority of women believed that ambiguity increased the
risk of developing cancer (Hanoch et al., 2014). From
these results, the study concluded that health care professionals should increase measures to ensure correct interpretation of uninformative-negative and ambiguous results
for patients (Hanoch et al., 2014). However, with little
ability to treat variants of uncertain significance, it is difficult for medical professionals to fully communicate risks
to patients. A VUS or benign result is clinically interpreted
as a negative risk, but this is not how patients interpret the
result.
Beyond issues with interpreting CGT results, recent
studies suggest that people who learn their genetic risk of
certain cancers often do not even take any actions with their
results (Rapaport, 2016). A study conducted in California
analyzed survey data from 762 customers who used directto-consumer cancer-risk profiles to assess their cancer
genetic risk. After 6 months, the study found that people
who were at a higher risk of developing neoplasms were no
more likely than those with an average risk to change their
diet, exercise, or to seek cancer screening. The study concluded that personalized CGT will not hold any “medical
crystal ball” and that they alone will not even necessarily
encourage patients to take action based on their results
(Rapaport, 2016).
Risk management recommendations for VUS results are
based on genetic and familial risk. Myriad Genetics, a molecular diagnostic company, recommends that clinical management of VUS carriers be based upon personal and family
history and not the presence or absence of the variant itself.
Each report given to patients after testing includes “guideline-based medical management considerations for negative
and positive patients (either of which may contain variants of
uncertain significance), and information for family members” (Myriad Genetics Laboratories, 2018). Some health
care providers choose to increase surveillance or pursue
treatment options beyond that recommended for such variants (Plon et al., 2011). Still, there is no explicitly defined
follow-up plan for VUS results. The unclear course of treatment to pursue after receiving a VUS result may bring feelings of increased anxiety for patients who undergo CGT.
Challenges such as this surrounding the communication and
interpretation of cancer panel testing present the potential for
ethical turmoil.

Limitations in the Literature
Limitations in the extant literature on CGT are varied.
Further research is needed regarding the psychosocial implications of CGT as a whole. It is becoming increasingly
important to understand the impact of providing personalized risk assessments via panel testing to implement a genetic
testing process that enhances both the experience of patients
and the clinical utility of the testing (Hiraki et al., 2014). In
addition, the growing interest in CGT may require standardized tools to fully understand and generalize the cognitive
aspects of patients who undergo testing (Schlich-Bakker
et al., 2006).
Many studies regarding the psychosocial implications of
CGT provided the mean age of those who participated in the
study. Most of the participants, both male and female, were
from a wide age range, averaging around 47. This points to
the importance of focusing on the influence of an individual’s stage in life to understand the emotional impact of
genetic testing and a potential cancer diagnosis (SchlichBakker et al., 2006). More specifically, studying women
under the age of 45 may present different psychosocial
implications because these women potentially have young
children, extensive responsibilities, and the expectation for a
long life (Claes et al., 2004).
In addition to focusing on young females who undergo
genetic testing, more research is needed on those who receive
an inconclusive test result (Schlich-Bakker et al., 2006).
Much of the literature neglects to discuss the psychosocial
implications of an unclear or variant of unknown significance result on patients participating in CGT (Voorwinden &
Jaspers, 2016). Along these lines, future research is necessary on how genetic models predict cancer risk and to determine the frequency and predictive values of less common
variants (Hiraki et al., 2014).
Common limitations in the literature surrounding CGT
and the related psychosocial and ethical implications involve
small or homogeneous samples (Aspinwall et al., 2011;
Pasacreta, 2003), lack of studies carried out in the United
States (Bennett et al., 2012; Eijzenga et al., 2014; Ho et al.,
2010; Tuinman et al., 2008), and a lack of qualitative study
(Aspinwall et al., 2011; Hanoch et al., 2014; Hermel et al.,
2016; Pasacreta, 2003).

Conclusion
The past 20 years have seen significant improvements in
the field of CGT. Genetic testing is an excellent avenue
for early identification of hereditary cancer syndromes
and for prompt risk management and tailored treatment.
Genetic counseling provides a personalized experience
for patients and has been known to reduce patients’ anxiety associated with a cancer diagnosis. Both qualitative
and quantitative studies have been conducted to understand the psychosocial and ethical implications of genetic
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testing in regard to both patient care and clinical utility.
Established literature regarding the history, role of nurses,
and the psychosocial and ethical implications of CGT
reveals a need for future research to fill the current gap
that exists surrounding the psychosocial implications of
cancer genetic panel testing, particularly with regard to
incidental findings.
Further research in this area will be critical in defining the
future of the nurse’s role in CGT. This research will provide
a pathway for nursing programs to include CGT in their curriculums and to set clearer expectations for nurses in this setting. With improved patient outcomes in mind, the practice
of CGT as a whole will continue to progress with further
research as nurses, and other health care professionals are
made more aware of how these practices affect patients
psychosocially.
Acknowledgment
The authors would like to acknowledge Elizabeth Shieh of the
Knoxville Comprehensive Breast Center.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
American Academy of Pediatrics Committee on Bioethics. (2001).
Ethical issues with genetic testing in pediatrics. Pediatrics,
107, 1451-1455. doi:10.1542/peds.107.6.1451
American Cancer Society. (2018). Cancer facts & figures 2018.
Atlanta, GA: Author. Retrieved from https://www.cancer.org/
content/dam/cancer-org/research/cancer-facts-and-statistics/
annual-cancer-facts-and-figures/2018/cancer-facts-and-fig
ures-2018.pdf
American Nurses Credentialing Center. (2016). Genetics nursing. Retrieved from http://allnurseprograms.com/geneticsnursing/
Aspinwall, L. G., Taber, J. M., Leaf, S. L., Kohlmann, W., &
Leachman, S. A. (2013). Genetic testing for hereditary melanoma and pancreatic cancer: A longitudinal study of psychological outcome. Psycho-Oncology, 22, 276-289. doi:10.1002/
pon.2080
Badzek, L., Calzone, K. A., Jenkins, J., Culp, S., & Bonham, V. L.
Jr. (2013). Nursing leaders hold the key to translating genomics
into practice. American Nurse Today, 8(12), 20-21.
Baylin, S. B., & Jones, P. A. (2012). A decade of exploring the
cancer epigenome—Biological and translational implications.
Nature Reviews Cancer, 11, 726-734. doi:10.1038/nrc3130
Bennett, P., Phelps, C., Hilgart, J., Hood, K., Brain, K., & Murray,
A. (2012). Concerns and coping during cancer genetic risk
assessment. Psycho-Oncology, 21, 611-617. doi:10.1002/
pon.1938

SAGE Open
Boveri, T. (1929). The origin of malignant tumors. Baltimore, MD:
Williams & Wilkins.
Burt, R., & Neklason, D. W. (2005). Genetic testing for inherited
colon cancer. Gastroenterology, 128, 1696-1716. doi:10.1053/j.
gastro.2005.03.036
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G.,
Delaloge, S., . . .Piccart, M. (2016). 70-gene signature as an
aid to treatment decisions in early-stage breast cancer. New
England Journal of Medicine, 375, 717-729. doi:10.1056/
NEJMoa1602253
Chang, J. T., Gatza, M. L., Lucas, J. E., Barry, W. T., Vaughn, P.,
& Nevins, J. R. (2011). SIGNATURE: A workbench for gene
expression signature analysis. BMC Bioinformatics, 12, Article
443. doi:10.1186/1471-2105-12-443
Claes, E., Evers-Kiebooms, G., Boogaerts, A., Decruyenaere,
M., Denayer, L., & Leguis, E. (2004). Diagnostic genetic
testing for hereditary breast and ovarian cancer in cancer patients: Women’s looking back on the pre-test period
and a psychological evaluation. Genetic Testing, 8, 13-21.
doi:10.1089/109065704323015996
Durmaz, A. A., Karaca, E., Demkow, U., Toruner, G., Schoumans,
J., & Cogulu, O. (2015). Evolution of genetic techniques: Past,
present, and beyond. Biomed Research International, 2015,
Article 461524. doi:10.1155/2015/461524
Eijzenga, W., Bleiker, E. M. A., Hahn, D. E. E., Kluijt, H. I.,
Sidharta, G. N., Gundy, C., & Aaronson, N. K. (2014).
Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire: Development and testing of a screening questionnaire for
use in clinical cancer genetics. Psycho-Oncology, 23, 862-869.
doi:10.1002/pon.3485
Facing Our Risk of Cancer Empowered. (2016). National
Comprehensive Cancer Network guidelines for genetic counseling. Available from facingourrisk.org
Galiatsatos, P., Rothenmund, K., Aubin, S., & Foulkes, W. D.
(2015). Psychosocial impact of lynch syndrome on affected
individuals and families. Digestive Diseases & Sciences, 60,
2246-2250. doi:10.1007/s10620-015-3626-8
Gomy, I., & Estevez Diz, M. D. P. (2013). Hereditary cancer risk assessment: Essential tools for a better approach. Hereditary Cancer in
Clinical Practice, 11, Article 16. doi:10.1186/1897-4287-11-16
Hanoch, Y., Miron-Shatz, T., Rolinson, J. J., & Ozanne, E. (2014).
Understanding of BRCA1/2 genetic test results: The importance of objective and subjective numeracy. Psycho-Oncology,
23, 1142-1148. doi:10.1002/pon.3537
Hermel, D. J., McKinnon, W. C., Wood, M. E., & Greenblatt, M. S.
(2016). Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. Familial Cancer, 16,
159-166. doi:10.1007/s10689-016-9913-5
Hiraki, S., Rinella, E. S., Schnabel, F., Oratz, R., & Ostrer, H.
(2014). Cancer risk assessment using genetic panel testing:
Considerations for clinical application. Journal of Genetic
Counseling, 23, 604-617. doi:10.1007/s10897-014-9695-6
Hirschberg, A. M., Chan-Smutko, G., & Pirl, W. F. (2015).
Psychiatric implications of cancer genetic testing. Cancer, 121,
341-360. doi:10.1002/cncr.28879
Ho, S. M. Y., Ho, J. W. C., Bonanno, G. A., Chu, A. T. W., & Chan,
E. M. S. (2010). Hopefulness predicts resilience after hereditary
colorectal cancer genetic testing: A prospective outcome trajectories study. BioMed Central Cancer, 10, 279-289. Retrieved from
http://www.biomedcentral.com/1471-2407/10/279

Harris and Hutson
Kouzarides, T. (2007). Chromatin modifications and their function.
Cell, 128, 693-705. doi:10.1016/j.cell.2007.02.005
Lea, D. (2008). Genetic and genomic healthcare: Ethical
issues of importance to nurses. The Online Journal of
Issues in Nursing, 13(1), Manuscript 4. doi:10.3912/OJIN.
Vol13No01Man04
Matloff, E. T., Bonadies, D. C., Moyer, A., & Brierley, K. L.
(2014). Changes in specialists’ perspectives on cancer genetic
testing, prophylactic surgery and insurance discrimination:
Then and now. Journal of Genetic Counseling, 23, 164-171.
doi:10.1007/s10897-013-9625-z
Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Nextgeneration sequencing for cancer diagnostics: A practical
perspective. The Clinical Biochemist Reviews/Australian
Association of Clinical Biochemists, 32, 177-195.
Mendel, G. (1865). Experiments in plant hybridization. Czech
Republic: Classical Genetics. Electronic Scholarly Publishing
Project. Retrieved from http://www.esp.org/foundations/genetics/classical/gm-65.pdf
Myriad Genetics Laboratories. (2018). Variants of uncertain significance: What you need to know. Retrieved from https://www.
myriadpro.com/blog/variants-of-uncertain-significance-whatyou-need-to-know/
Nagy, R., Sweet, K., & Eng, C. (2004). Highly penetrant hereditary
cancer syndromes. Oncogene, 23, 6445-6470. doi:10.1038/
sj.onc.1207714
National Cancer Institute. (2016). Genetic testing for hereditary cancer syndromes. Retrieved from http://www.cancer.gov/aboutcancer/causes-prevention/genetics/genetic-testing-fact-sheet
National Institutes of Health. (2010). Genetic testing:
How it is used for healthcare. Retrieved from https://
report.nih.gov/nihfactsheets/Pdfs/GeneticTestingHowItIsUsedForHealthcare(NHGRI).pdf
National Society of Genetic Counselors. (2016). About genetic
counselors. Retrieved from http://www.nsgc.org/page/geneticcounseling-training-page
Ormond, K. E., Wheeler, M. T., Hudgins, L., Klein, E. T., Butte, A.
J., Altnan, R. B., . . . Greely, H. T. (2010). Challenges in the
clinical application of whole-genome sequencing. The Lancet,
375, 1749-1751. doi:10.1016/S0140-6736(10)60599-5
Pasacreta, J. V. (2003). Psychosocial issues associated with genetic
testing for breast and ovarian cancer risk: An integrative
review. Cancer Investigation, 21, 588-623. doi:10.1081/CNV120022380
Pasche, B., & Absher, D. (2011). Whole-genome sequencing: A step closer to personalized medicine. Journal of the
American Medical Association, 305, 1596-1597. doi:10.1001/
jama.2011.484
Patenaude, A. F., & Julian-Reynier, C. (2008). Cancer genetic testing: Current and emerging issues. Psycho-Oncology, 17, 733736. doi:10.1002/pon.1419
Phillips, B. J. (2006). The ethics of genetic testing and the role of the
professional nurse in practice [PowerPoint slides]. Retrieved
from http://commons.emich.edu/cgi/viewcontent.cgi?article=1
011&context=honors
Plon, S. E., Cooper, H. P., Parks, B., Dhar, S. U., Kelly, P. A.,
Weinberg, A. D., . . . Hilsenbeck, S. (2011). Genetic testing and
cancer risk management recommendations by physicians for

9
at-risk relatives. Genetics in Medicine: Official Journal of the
American College of Medical Genetics, 13, 148-154.
Rahman, N., & Scott, R. H. (2007). Cancer genes associated with
phenotypes in monoallelic and biallelic mutation carriers: New
lessons from old players. Human Molecular Genetics, 16, 6066. doi:10.1093/hmg/ddm026
Rapaport, L. (2016, December 14). Personal-genome cancer-risk
profile may not inspire lifestyle changes. Reuters. Retrieved
from http://www.reuters.com/article/us-health-genomics-can
cer-profile-idUSKBN1422KN
Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing
with chain-terminating inhibitors. Proceedings of the National
Academy of Sciences of the United States of America, 74,
5463-5467. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC431765/
Santos, E. M. M., Edwards, Q. T., Santos, M. F., Rogatto, S. R.,
Achatz, M. I. W., & MacDonald, D. J. (2012). Integration of
genomics in cancer care. Journal of Nursing Scholarship, 45,
43-51. doi:10.1111/j.1547-5069.2012.01465.x
Schlich-Bakker, K. J., ten Kroode, H. F. J., & Ausems, M. G. E.
M. (2006). A literature review of the psychological impact of
genetic testing on breast cancer patients. Patient Education and
Counseling, 62, 13-20. doi:10.1016/j.pec.2005.08.012
Stoffel, E. M., & Chittenden, A. (2010). Genetic testing for hereditary colorectal cancer: Challenges in identifying, counseling,
and managing high-risk patients. Gastroenterology, 139, 14361441. doi:10.1053/j.gastro.2010.09.018
Surbone, A. (2001). Ethical implications of genetic testing for breast
cancer susceptibility. Oncology/Hematology, 40, 149-157.
Susan G. Komen Foundation. (2018). Quality of screening tests:
Sensitivity and specificity. Retrieved from https://ww5.komen.
org/BreastCancer/QualityofScreeningTests.html
Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J.
H., . . . Bamshad, M. J. (2012). Informed consent for whole genome
sequencing: A qualitative analysis of participant expectations and
perceptions of risks, benefits, and harms. American Journal of
Medical Genetics, 158A, 1310-1319. doi:10.1002/ajmg.a.35328
Tavtigian, S. V., Greenblatt, M. S., Goldgar, D. E., & Boffetta, P.
(2008). Assessing pathogenicity: Overview of results from the
IARC unclassified genetic variants working group. Human
Mutation, 29, 1261-1264. doi:10.1002/humu.20903
Tuinman, M. A., Gazendam-Donofrio, S. T., & Hoekstra-Weebers,
J. E. (2008). Screening and referral for psychosocial distress in
oncologic practice: Use of the distress thermometer. Cancer,
113, 870-878. doi:10.1002/cncr.23622
Umberger, R., Holston, E. C., Hutson, S. P., & Pierce, M. (2013).
Nursing genomics: Practice implications every nurse should
know. Nursing Clinics of North America, 48, 511-516.
doi:10.1016/j.cnur.2013.08.006
Voorwinden, J. S., & Jaspers, J. P. C. (2016). Prognostic factors for distress after genetic testing for hereditary cancer. Journal of Genetic
Counseling, 25, 495-503. doi:10.1007/s10897-015-9894-9
Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M.,
Pennil, C., . . . King, M. C. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and
massively parallel sequencing. Proceedings of the National
Academy of Science of the United States of America, 107,
12629-12633. doi:10.1073/pnas.1007983107

10
Watson, J. D., & Crick, F. H. (1953). A structure for deoxyribose
nucleic acid. Nature, 171, 737-738

Author Biographies
Gillian P. Harris is a registered nurse in Knoxville, TN. While
pursuing her nursing degree, she was involved as a nursing student
ambassador, a resident assistant, a First-Year Studies Peer Mentor,
and the UT Student Nurses Association president. As a student in
the Nursing Honors Program, she focused her research on the psychosocial responses to and decision-making strategies of hereditary
cancer risk assessment testing by interviewing women at the
Knoxville Comprehensive Breast Center. Harris intends to seek
employment in adult oncology and to further her education by pursuing a Doctorate in Nursing Practice degree.
Sadie P. Hutson earned a PhD in nursing from the University of
Pennsylvania and an MSN as a Women’s Health Nurse Practitioner
from the University of Pennsylvania, Philadelphia, PA.
Additionally, she received a BSN from the University of

SAGE Open
Wisconsin, Madison. Hutson teaches in the BSN, MSN, and PhD
programs at the University of Tennessee, College of Nursing. Her
areas of interest in teaching are research methods, philosophy of
science, and grant writing. Her areas of scientific interest include
studying the consequences of living with chronic illness in rural
and underserved areas, specifically Appalachia. Her work was
recently funded by the National Institute of Nursing Research to
explore the advanced care planning needs of persons living with
HIV/AIDS in Appalachia. Hutson is an active member of several
professional organizations including the Hospice and Palliative
Nurses Association, Sigma Theta Tau, and the Association of
Nurses in AIDS Care. Hutson is on the editorial board for the
American Journal of Hospice and Palliative Medicine. She is also
the project lead for a community project/non-profit organization
called Appalachian Angel of Hope. She serves as a faculty senator
and an officer in the faculty senate, serving in the role of senate
secretary.

